Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
COMBINATION_PRODUCT

Ixazomib and Daratumumab

"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."

Trial Locations (1)

14033

RECRUITING

CHU CAEN Dept of Hematology, Caen

All Listed Sponsors
lead

University Hospital, Caen

OTHER